Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients
Details
Publication Year 2023-02,Volume 64,Issue #1,Page 131-137
Journal Title
Australasian Journal of Dermatology
Publication Type
Case report
Abstract
We present a case series of 13 patients, the first Australian single-centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T-lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.
Publisher
Wiley
Keywords
Humans; Australia; B7-H1 Antigen/drug effects; Cell Death; *Pemphigoid, Bullous/etiology/pathology; *Immune Checkpoint Inhibitors/adverse effects/therapeutic use; bullous pemphigoid; immune check point inhibitor; immune-related adverse events; immunotherapy
Department(s)
Surgical Oncology
PubMed ID
36514287
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-15 07:25:01
Last Modified: 2023-06-15 07:25:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙